Look­ing to blend AI and hu­man da­ta, Va­lo Health scores new fi­nanc­ing to test drug dis­cov­ery plat­form in on­col­o­gy, be­yond

Com­pa­nies look­ing to bring ma­chine learn­ing in­to drug dis­cov­ery are a dime a dozen, but Boston-based Va­lo Health be­lieves its pro­pri­etary plat­form could give it a leg up in iden­ti­fy­ing can­di­dates for a range of ther­a­peu­tic ar­eas. Now, in­vestors are plac­ing a big down pay­ment to see if Va­lo is right.

Va­lo Health, which aims to merge AI with hu­man da­ta to for­mu­late can­cer ther­a­peu­tics and be­yond, has closed a $190 mil­lion Se­ries B fi­nanc­ing round. Va­lo said the fi­nanc­ing will ex­pe­dite sev­er­al new ther­a­peu­tic pro­grams us­ing the com­pa­ny’s nov­el drug de­vel­op­ment plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER